Other Events ·
Tempest Therapeutics adjourns special meeting to vote on governance changes after failing to secure required supermajority
TPSTTempest Therapeutics, Inc.
Tempest Therapeutics adjourned its reconvened special stockholder meeting because the proposal to replace specified supermajority voting requirements and permit stockholder action by written consent failed to receive the necessary affirmative vote of at least 75% of all outstanding shares. The company engaged a proxy solicitation firm to assist in obtaining adequate votes for the measure, which requires approval by holders of at least seventy-five percent of the total votes entitled to be cast. The meeting is scheduled to reconvene on November 12, 2026, via live webcast. Tempest Therapeutics operates as a clinical-stage biotechnology company focused on developing treatments for rare diseases.